Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | F13A1 | P00488 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | TGM1 | P22735 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23389815 | 0.98 | KDM4E (0.45) | KDM4EF13A1TGM2TGM1MAPT | |
| SCHEMBL28831827 | 0.86 | KDM4E (0.39) | KDM4EF13A1TGM2TGM1MAPT | |
| SCHEMBL20546681 | 0.82 | POLB (0.35) | KMT2ABTKTSHRSMYD3 | |
| SCHEMBL10803979 | 0.82 | — | — | |
| SCHEMBL13970069 | 0.82 | POLB (0.35) | KMT2ABTKTSHRSMYD3 | |
| SCHEMBL4256096 | 0.77 | CA1 (0.43) | KDM4EF13A1TGM2TGM1USP2 | |
| SCHEMBL3598091 | 0.76 | KDM4E (0.46) | KDM4EF13A1TGM2TGM1MAPT | |
| SCHEMBL2428756 | 0.75 | CA1 (0.48) | KDM4EF13A1TGM2TGM1MAPT | |
| SCHEMBL3548115 | 0.72 | KDM4E (0.52) | KDM4EF13A1TGM2TGM1MAPT | |
| SCHEMBL3554550 | 0.71 | SMYD3 (0.33) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111499313-B | Cement-based aerogel heat insulation board and preparation method thereof | 贵州航天建设工程有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-111499313-A | Cement-based aerogel heat-insulation plate and preparation method thereof | 贵州航天建设工程有限公司 | 2020-08-07 | — | — | CN | claimed |
| EP-4637926-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2025-10-29 | — | — | EP | disclosed |
| CN-111499313-B | Cement-based aerogel heat insulation board and preparation method thereof | 贵州航天建设工程有限公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2024132278-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024132278-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-20230052528-A1 | TASPASE1 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-02-16 | — | — | US | disclosed |
| CN-115397818-A | Aminopyrimidine derivatives and their use as modulators of arene receptors | 东亚ST株式会社 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021102359-A2 | TASPASE1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| CN-111499313-A | Cement-based aerogel heat-insulation plate and preparation method thereof | 贵州航天建设工程有限公司 | 2020-08-07 | — | — | CN | disclosed |
| EP-2029606-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-0986551-B1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-6359134-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| EP-0986551-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052528-A1 | TASPASE1 INHIBITORS AND USES THEREOF | RNASE1, TASP1, TPP1 | KDM4E 3697/4885F13A1 4092/4885TGM2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.